Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04887012
Other study ID # IR2021002168
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 1, 2021
Est. completion date May 1, 2024

Study information

Verified date May 2021
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Wenbin Qian
Phone +8613605801032
Email qianwb@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To study the safety and effectiveness of HLA haploidentical CAR-NK cells targeting CD19 in patients with B-cell non-Hodgkin's lymphoma


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date May 1, 2024
Est. primary completion date May 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Volunteer to participate in this study and sign an informed consent form; 2. Age 18-75 years old, no gender limit; 3. Histologically diagnosed as diffuse large B-cell lymphoma (DLBCL), transforming follicular lymphoma (TFL), primary mediastinal B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL) and other inert B-cells NHL conversion type: - Refractory or relapsed DLBCL refers to the failure to achieve complete remission after 2-line treatment; disease progression during any treatment, or disease stable time equal to or less than 6 months; or disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation ; - Refractory or relapsed MCL must be resistant to or intolerable to BTK inhibitors; - Refractory or relapsed indolent B-cell NHL is the failure or recurrence of third-line treatment; - Previous treatment must include CD20 monoclonal antibody treatment (unless the subject is CD20 negative) and anthracyclines; 4. At least one measurable lesion with the longest diameter = 1.5 cm exists; 5. The expected survival period is =12 weeks; 6. The puncture section of the tumor tissue was positive for CD19 expression; 7. ECOG score 0-2 points; 8. Sufficient organ function reserve: - Alanine aminotransferase, aspartate aminotransferase = 2.5× UNL (upper limit of normal value); - Creatinine clearance rate (Cockcroft-Gault method) =60 mL/min; - Serum total bilirubin and alkaline phosphatase =1.5× UNL; - Glomerular filtration rate>50Ml/min - Cardiac ejection fraction (EF) =50%; - Under natural indoor air environment, basic oxygen saturation>92% 9. Allow a previous stem cell transplantation 10. The approved anti-B-cell lymphoma treatments, such as systemic chemotherapy, systemic radiotherapy, and immunotherapy, have been completed for at least 3 weeks before the study medication; 11. Allow patients who have previously received CAR-T cell therapy and have failed or relapsed after 3 months of evaluation; 12. Female subjects of childbearing age must have a negative pregnancy test and agree to take effective contraceptive measures during the trial 13. Two tests for the new coronavirus were negative. Exclusion Criteria: 1. Those who have a history of allergies to any of the ingredients in cell products; 2. History of other tumors 3. Previously presented with II-IV degree (Glucksberg criteria) acute GvHD or extensive chronic GvHD; or are receiving anti-GvHD treatment; 4. Have received gene therapy in the past 3 months; 5. Active infections that require treatment (except for simple urinary tract infections and bacterial pharyngitis), but preventive antibiotics, antiviral and antifungal infection treatments are allowed; 6. Hepatitis B (HBsAg positive, but HBV-DNA <103 is not an exclusion criterion) or hepatitis C virus infection (including virus carriers), syphilis and other subjects with acquired and congenital immunodeficiency diseases, including But not limited to people living with HIV; 7. According to the New York Heart Association's Heart Function Classification Standard, it is classified as Grade III or Grade IV. Impaired subjects; 8. Those who have received anti-tumor therapy in the early stage but the toxic reaction has not recovered (the CTCAE 5.0 toxic reaction has not recovered to =1, except for fatigue, anorexia, and hair loss); 9. Subjects with a history of epilepsy or other central nervous system diseases; 10. Enhanced CT or MRI of the head showed evidence of central nervous system lymphoma; 11. Have received any other drugs that target CD19; 12. Women who are breastfeeding and unwilling to stop breastfeeding; 13. Any other situation that the investigator believes may increase the risk of the subject or interfere with the results of the test.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
anti-CD19 CAR-NK
lentiviral vector-transducted HLA haploidentical NK cells to express anti-CD19 CAR

Locations

Country Name City State
China 2nd Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of dose limiting toxicity (DLTs) To evaluate the safety, tolerability, and determine the recommended dosage of Anti-CD19 CAR-NK Cell Therapy for B-cell Non-Hodgkin Lymphoma Up to 28 days
Primary The overall response rate(ORR) To determine the anti-tumor effectivity of CAR-NK019 Up to 2 years
Secondary Overall survival (OS) To determine the anti-tumor effectivity of CAR-NK019 Up to 2 years
Secondary progression free survival (PFS) To determine the anti-tumor effectivity of CAR-NK019 Up to 2 years
Secondary Pharmacokinetics of CAR positive cells The copy number of CAR DNA was measured at the preset follow-up time point. Up to 2 years
Secondary Pharmacokinetics of CAR-NK cells The duration of CAR-positive NK cells in circulation was measured by FACs Up to 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03114865 - A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance Phase 1/Phase 2
Recruiting NCT04836195 - Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma Phase 1
Active, not recruiting NCT04088890 - Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies Phase 1
Recruiting NCT05472558 - Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL Phase 1
Recruiting NCT04191941 - Treatment of Hematological Malignancy With Novel CAR-T Cells. Early Phase 1
Active, not recruiting NCT04148430 - A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy Phase 2
Recruiting NCT05702853 - Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL Phase 1/Phase 2
Not yet recruiting NCT05991388 - A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Phase 2/Phase 3
Completed NCT04030195 - Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL Phase 1/Phase 2
Recruiting NCT04594642 - A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Phase 1
Recruiting NCT05338931 - Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Recruiting NCT05164770 - Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Phase 3
Completed NCT05260203 - MargheRITA (Remote Intelligence for Therapeutic Adherence) N/A
Active, not recruiting NCT05094206 - CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies Phase 1
Recruiting NCT06392477 - A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Phase 1
Not yet recruiting NCT04412174 - A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL Early Phase 1
Completed NCT04748185 - Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies
Active, not recruiting NCT03283137 - Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL Phase 1
Completed NCT02910063 - Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL Phase 2/Phase 3
Recruiting NCT05744037 - Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells Phase 2